Tanning Peptides: Melanotan I vs Melanotan II — What the Evidence Actually Shows

Melanotan I and Melanotan II are both synthetic analogs of alpha-melanocyte-stimulating hormone (alpha-MSH), and both activate the MC1R receptor on melanocytes to stimulate melanin production — the pigment that gives skin its tan color. This is where the similarity ends. Melanotan I (afamelanotide, brand name Scenesse) is a selective MC1R agonist. It activates the tanning receptor with minimal activity at other melanocortin receptors. It's FDA-approved, has been tested in over 1,000 patients with some receiving continuous treatment for over 10 years, and has zero reported melanoma events in clinical settings. Melanotan II is a non-selective melanocortin agonist. It hits MC1R (tanning), MC3R (energy homeostasis), MC4R (appetite and sexual function), and MC5R (exocrine glands). It has never been approved anywhere in the world. It's sold illegally online and at tanning salons, often as nasal sprays or injectable vials with unknown purity and dosing. Multiple case reports link it to melanoma development. The distinction matters enormously, and most people using "melanotan" have no idea which one they're getting — or that the difference could be the difference between a well-characterized medication and an uncontrolled experiment on their skin.

The melanocortin-1 receptor (MC1R) sits on the surface of melanocytes — the cells that produce skin pigment. When alpha-MSH (or a synthetic analog) binds MC1R, it triggers a signaling cascade: increased cAMP activates tyrosinase, the rate-limiting enzyme in melanin synthesis, shifting production toward eumelanin (brown/black protective pigment) and away from pheomelanin (red/yellow pigment associated with sun sensitivity and DNA damage). This is the same pathway UV exposure activates naturally. But here's the key insight from recent research: MC1R activation does more than just darken skin. It independently promotes DNA repair through nucleotide excision repair pathways, suppresses pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6), and induces immunosuppressive IL-10. These effects occur even separately from pigmentation changes. In other words, MC1R activation is inherently photoprotective — the receptor evolved to protect skin from UV damage. People with loss-of-function MC1R variants (common in fair-skinned populations) have a 2.2-fold increased melanoma risk with one variant and 4.1-fold with two. Activating MC1R pharmacologically does the opposite: it should reduce cancer risk, not increase it.

Afamelanotide was FDA-approved in 2019 as Scenesse for erythropoietic protoporphyria (EPP), a rare genetic condition causing extreme pain upon sun exposure. It's delivered as a subcutaneous implant — a small rod placed under the skin near the hip — that slowly releases the peptide over about 60 days. The clinical safety database is remarkably clean: - Over 1,000 patients exposed in clinical trials and post-marketing - Some patients received continuous treatment for more than 10 years - Zero melanoma events reported in this population - Only 2 new nevi reported in 115 patients over 8 years of follow-up - Side effects: implant site reactions, headache, nausea (generally mild) Afamelanotide's selectivity for MC1R means it produces tanning without the sexual side effects (erections, arousal), appetite changes, or nausea that Melanotan II causes through its MC3R/MC4R activity. The catch: Scenesse is approved only for EPP. It's expensive, implant-only, and not prescribed for cosmetic tanning. This gap between a safe, approved MC1R agonist and cosmetic demand is exactly what drives people to the gray market.

Melanotan II has never been approved by any regulatory agency anywhere in the world. Despite this, it's one of the most widely used gray-market peptides globally, sold as injectable vials, nasal sprays, and even premixed "tanning kits" through online vendors, social media, and some tanning salons. The appeal is obvious: visible tanning within days, even in very fair-skinned individuals, without extensive UV exposure. But the non-selective receptor profile creates a cascade of effects beyond skin darkening: - MC4R activation: spontaneous erections, increased libido, flushing (this is how PT-141/bremelanotide was discovered — it was originally a Melanotan II side effect) - MC3R activation: appetite suppression, energy metabolism changes - MC5R activation: effects on exocrine glands - Nausea, facial flushing, fatigue (common, especially early in use) - Darkening of existing moles and formation of new nevi - Reported cases of kidney dysfunction and cerebral edema The mole issue is particularly concerning for melanoma screening. Melanotan II darkens and modifies existing moles uniformly, making it harder to identify the asymmetry, border irregularity, and color variation that are warning signs of melanoma (the ABCDEs). Multiple dermatology case reports describe melanoma diagnosed in Melanotan II users — including a 20-year-old woman who developed melanoma after just 3-4 weeks of use.

Five melanoma cases have been documented in Melanotan II users in the published literature. The critical question is whether MT-II caused the melanoma, or whether increased skin surveillance in users who noticed mole changes led to earlier detection of melanomas that would have developed regardless. The evidence is nuanced: **Against MT-II causing melanoma:** A comprehensive 2024 review found that "long-term activation of MC1R, either physiologically or pharmacologically, has not been shown to be associated with increased incidence of melanoma." MC1R activation is inherently protective — it promotes DNA repair and eumelanin production. Afamelanotide showed zero melanomas in 1,000+ patients over 10+ years. **Complicating factors:** All documented MT-II melanoma cases involved patients with pre-existing risk factors: fair skin, extensive UV/tanning bed exposure, and genetic predisposition. MT-II users typically combine the peptide with UV exposure (tanning beds or sun) to "activate" the tan — the UV is the known carcinogen, not necessarily the peptide. **The real danger may be behavioral:** MT-II gives fair-skinned people a false sense of protection. They may increase UV exposure believing their darker skin protects them. Eumelanin does provide some UV protection, but pheomelanin-dominant skin types don't fully convert to eumelanin, and MT-II-induced pigmentation may not provide the same protection as natural tanning. **The mole-masking problem is real regardless:** Even if MT-II doesn't directly cause melanoma, it objectively interferes with melanoma screening by altering mole appearance — and this alone is a significant clinical concern.

Melanotan II nasal sprays have exploded on TikTok and Instagram, marketed with before/after tan transformation photos and branded as a safe alternative to UV tanning. The reality is that these products carry risks beyond even the peptide itself. **Contamination:** Because MT-II is manufactured in unregulated facilities, there is no guarantee of purity. Products may contain incorrect doses, degradation products, bacterial endotoxins, or entirely different compounds. A 2024 dermatology commentary in Cutis highlighted that consumers "risk inhaling or injecting contaminated chemicals." **Dosing inconsistency:** Without pharmaceutical-grade manufacturing, peptide concentrations vary between batches and between vendors. Users have no way to know their actual dose. **Nasal delivery concerns:** The nasal mucosa is highly vascular, providing rapid systemic absorption — but also making the brain vulnerable. Reports of cerebral edema (brain swelling) have been associated with melanotan use. **No medical oversight:** Unlike prescribed medications, gray-market melanotan comes with no baseline skin exam, no monitoring for mole changes, and no follow-up. Users who develop suspicious moles may not recognize them as concerning because they expect mole changes as a "normal" effect of the peptide.

Two other drugs that activate melanocortin receptors are FDA-approved, providing additional safety data on this receptor family: **PT-141 (bremelanotide, Vyleesi):** Approved for hypoactive sexual desire disorder in women. Originally discovered as a Melanotan II side effect. Activates MC4R preferentially. In 684 treated patients, zero malignant melanomas were reported. Only mild, resolved nevus cases occurred. Tanning is a known side effect but not the primary indication. **Setmelanotide (Imcivree):** Approved for rare genetic obesity disorders (MC4R pathway mutations). In 926 treated patients, 56% experienced hyperpigmentation. Two melanoma cases occurred — but both patients had extensive pre-existing risk factors (fair skin, equatorial sun exposure, genetic predisposition), and both were early-stage (pT1a) and successfully treated. The combined clinical database across all approved MC1R/MC4R agonists (afamelanotide + bremelanotide + setmelanotide) includes over 2,600 patients with a remarkably low melanoma signal — consistent with the biological expectation that MC1R activation is protective rather than carcinogenic.

**If you're considering Melanotan II nasal spray or injections:** You are using an unapproved, unregulated substance with unknown purity, inconsistent dosing, non-selective receptor activation (causing systemic effects beyond tanning), documented melanoma case reports, and interference with skin cancer screening. The behavioral risk of combining MT-II with increased UV exposure compounds every other risk. There is no legitimate medical supervision pathway for cosmetic MT-II use. **If you're interested in the science:** The MC1R pathway itself is well-validated for photoprotection, and selective MC1R agonism (as with afamelanotide) has an excellent safety record. The problem isn't the receptor — it's the specific compound, the non-selectivity, the lack of regulation, and the combination with UV exposure. **What to tell your dermatologist:** If you've used melanotan products, disclose this during skin exams. Altered mole appearance makes screening harder, and your dermatologist needs to know. A baseline dermoscopy after stopping use can help re-establish monitoring benchmarks. **The regulatory gap:** There is a genuine unmet demand for a safe, approved cosmetic tanning product. Afamelanotide proves the concept — selective MC1R activation works and is safe long-term. But until a cosmetic indication is pursued (which pharmaceutical economics may not support for an implant), the gap will continue to be filled by gray-market Melanotan II.